Filing Details

Accession Number:
0000947871-10-001073
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-11-22 16:39:10
Reporting Period:
2010-11-18
Filing Date:
2010-11-22
Accepted Time:
2010-11-22 16:39:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1053369 Elite Pharmaceuticals Inc ELTP Pharmaceutical Preparations (2834) 223542636
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1133880 Trellus Partners Lp 350 Madison Avenue, 9Th Floor
New York, NY 10017
No No Yes No
1211019 Trellus Partners Ii Lp 350 Madison Avenue, 9Th Floor
New York, NY 10017
No No Yes No
1307877 Trellus Management Company, Llc 350 Madison Avenue, 9Th Floor
New York, NY 10017
No No Yes No
1458673 Ltd Fund Offshore Trellus 350 Madison Avenue, 9Th Floor
New York, NY 10017
No No Yes No
1459107 Adam Usdan C/O Trellus Management Company, Llc
350 Madison Avenue, 9Th Floor
New York, NY 10017
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2010-11-18 60,000 $0.06 22,468,671 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
Footnotes
  1. On November 18, 2010, Trellus Partners, L.P., a Delaware limited partnership ("TPLP") sold 60,000 shares of Common Stock.
  2. On November 18. 2010, following the reported transaction, TPLP owned 11,598,264 shares of Common Stock and held warrants to acquire 3,291,426 shares of Common Stock and Trellus Offshore Fund Limited, a Cayman Islands limited liability company ("TOF") owned 6,002,344 shares of Common Stock and held warrants to acquire 1,377,758 shares of Common Stock and Trellus Partners, L.P. II ("TPLPII") owned 165,000 shares of Common Stock and warrants to acquire 33,879 shares of Common Stock. Trellus Management Company, LLC ("Trellus") and Mr. Usdan each beneficially owned the Common Stock and warrants owned by TPLP and TOF, and TPLPII.
  3. Trellus is the investment adviser to TPLP, TOF, and TPLPII. Adam Usdan is the controlling principal and chief investment officer of Trellus. By reason of their investment discretion, Trellus and Mr. Usdan are reported herein as indirect beneficial owners of the securities described in this Form 4.
  4. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.